MacroGenics, Inc. (MGNX)

Market Cap	197.02M +27.6%
Revenue (ttm)	149.50M -0.3%
Net Income	-74.62M
EPS	-1.18
Shares Out	63.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,240,545
Open	3.030
Previous Close	3.000
Day's Range	2.983 - 3.230
52-Week Range	0.990 - 3.540
Beta	1.39
Analysts	Hold
Price Target	3.40 (+9.68%)
Earnings Date	Mar 9, 2026

About MGNX

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MG...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 10, 2013
• Employees: 341
• Stock Exchange: NASDAQ
• Ticker Symbol: MGNX
• Website: https://www.macrogenics.com

Financial Performance

In 2025, MacroGenics's revenue was $149.50 million, a decrease of -0.31% compared to the previous year's $149.96 million. Losses were -$74.62 million, 11.4% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for MGNX stock is "Hold." The 12-month stock price target is $3.4, which is an increase of 9.68% from the latest price.

Price Target

$3.4

(9.68% upside)

Analyst Consensus: Hold